Abstract
Cold and colleagues ( 1) report findings by menopausal hormone therapy (MHT) use without providing the hormone therapy category. Both estrogen plus progestin and estrogen alone are described as increasing breast cancer incidence and mortality in women without breast cancer history, citing 2 large observational studies published in 2019. However, not cited was a 2020 report from 2 Women’s Health Initiative randomized placebo-controlled trials with 27 347 postmenopausal women with no prior breast cancer and mammogram clearance, evaluating estrogen plus progestin and estrogen alone (for women with prior hysterectomy). After 20 years of follow-up and 1565 incident breast cancers, estrogen plus progestin increased breast cancer incidence, whereas estrogen alone decreased breast cancer incidence and breast cancer mortality ( 2). Against such randomized trial findings, it is inappropriate to report findings without describing the MHT therapy category because differential effects on breast cancer outcomes could be anticipated. The authors should provide this information.
Funding Information
  • National Cancer Institute (R01 CA119171, R01 CA10921)
  • Women’s Health Initiative
  • National Heart, Lung, and Blood Institute
  • National Institutes of Health
  • U.S. Department of Health and Human Services (HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, HHSN268201600004C, R25CA203650)

This publication has 7 references indexed in Scilit: